Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase NA 1Phase 2/3 1Phase 2 1

Status

Recruiting 4Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 1Head & Neck 1Breast 1

Conditions

Breast Neoplasms 1316Neoplasms 1104Carcinoma, Non-Small-Cell Lung 916Prostatic Neoplasms 747Colorectal Neoplasms 645Lung Neoplasms 621Neoplasm Metastasis 470Multiple Myeloma 444Leukemia, Myeloid, Acute 440Pancreatic Neoplasms 392Ovarian Neoplasms 388Melanoma 346Carcinoma, Hepatocellular 308Brain Neoplasms 290Squamous Cell Carcinoma of Head and Neck 285Recurrence 285Glioblastoma 260Stomach Neoplasms 252Head and Neck Neoplasms 250Precursor Cell Lymphoblastic Leukemia-Lymphoma 238Carcinoma, Renal Cell 237Lymphoma 235Triple Negative Breast Neoplasms 233Endometrial Neoplasms 221Uterine Cervical Neoplasms 217Hematologic Neoplasms 216Urinary Bladder Neoplasms 212Lymphoma, Non-Hodgkin 203Glioma 202Sarcoma 200

Interventions

pembrolizumab 1Radiotherapy, Intensity-Modulated 1Losartan 1LY3300054 1Gemcitabine 1Cisplatin 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Camurati-Engelmann Syndrome × 90 days × Clear all
NCT06788990 2026-06-02

FORTIFI-HN01

Bicara Therapeutics

Phase 2/3 Recruiting
650 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Camurati-Engelmann Syndrome, Head and Neck Neoplasms, Laryngeal Diseases

NCT05209776 2026-06-01

LI-ARVC

University Hospital, Toulouse

Phase NA Recruiting
80 enrolled

Camurati-Engelmann Syndrome, Inflammation, Arrhythmogenic Right Ventricular Dysplasia

NCT05637216 2026-04-24

Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients

Shaw Cancer Center

Phase 2 Recruiting
43 enrolled
Breast

Radiation Fibrosis Syndrome, Breast Neoplasms, Camurati-Engelmann Syndrome, Fibrosis, Inflammation

NCT06487624 2026-04-13

An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors

FBD Biologics Limited

Phase 1 Recruiting
50 enrolled
Lymphoid

Camurati-Engelmann Syndrome, Hodgkin Disease, Neoplasms

NCT02937272 2026-04-03

A Study of LY3200882 in Participants With Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
223 enrolled

Camurati-Engelmann Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡